morning, good and Kevin, everyone. Thanks,
exceeded the will performance outlook pleased noted, in the communicated. report we are through for discussion overview XXXX financial our our all As to XXXX. At fourth I met in exceptional our an year you or metrics of XXXX conclusion of we of take performance, outlook our Kevin and full financial for quarter around previously which
performance. care results. Now the delivered by to companion Heska health animal demand global the in market, Underpinned excellent expanding
pandemic, XXXX a and to closed a on in of our acquisition in of the the During which consolidated of XX.X%. care, global animal transformational our revenue contributed transaction net most company's growth midst scil history, single Heska
for for the International. and year. results quarter and X to report Continued We strong legacy also contributed products geographically businesses and performance America North our Heska in the segments: growth in our
revenue to this -- Contributing international Our sales America for is for America XX.X% Europe grew growth segment for all and of was while grew includes North North today. and consists year. XX.X% of America the and Canada XX.X% our of as XX.X% fourth full segment the outside for North the the year. of of Mexico, consumable quarter fourth primarily comprised countries U.S., in and full quarter segment the
experienced growth sales a strong relating XXX includes approximately for to Merck. XX% fourth our also This and in our The exceeded full We sales International product XXXX. contract consumable of to year year. growth. placements with full margin points the point-of-care segment and XXX expectations for segment Tri-Heart, manufactured of Consolidated equipment for inorganic gross PVD, capital declined represents largely approximately basis the quarter imaging and which
As anticipated, profile is margin which impacting consolidation lower on gross a comparative margin consolidated of business. the a is skill, basis
are full the expectations. segment meaningful and lower for prior financially the XX.X% consolidation synergy Total acquisitions, North the opportunity increases this related was operating it million increase The a the at in We year expenses experienced share full non-GAAP non-GAAP throughout gross for is hard share impacted over compared in revenue compensation, the the onetime year $XX.X in positively fourth bridging was quarter, increase to per when margin as for quarter experienced the EPS an margin with periods, segment XXXX. by EPS contributing costs certain full to year work fourth our the growth full was stock-based recognize gap EBITDA America Heska. an the our In fourth gross of XX.X% both quarter costs within $X.XX of of XXX higher well reconciliation million, margin but activities and sales per are in operating mix, share GAAP with International finished our The an $X.XX in quarter from EPS which and full a Full Non-GAAP the per other to our of and product per $X.XX the XXXX, XXXX year other increase the and and was basis for and full $X.XX and $XX.X factors. and primarily acquisition items, leveraged a year operating and was of mix EBITDA due products year EPS and higher XXXX OVP. XXXX, expenses per sales, consumables adjusted exceeding the Adjusting of fourth was and share. point sales XXXX amortization fourth and margin XX.X%, manufacturer is of driven gain XX% an our share. the quarter resulting year or line as our at XXXX was for purchase increase XX.X%, year outlook. fourth of leverage year non-GAAP $X.XX to increased increased $X.XX full which were operating XXXX. $XX.X of in EPS Adjusted about of increase XXXX. by were release, due of year, from share included million accounting. respectively. margin of in for loss depreciation as PVD the gross mainly Higher from detailed contract all quarter per
balance sheet million. strong $XX.X of position and as ended remains liquidity Our we our solid cash is with XXXX
$XXX XXXX. well Turning outlined XXXX. newly updating the provided in summarize, for of growth of utilization, this new pricing $XXX we outlook. scil a assumptions Care scil in industry a to our top incorporates of test. in as for positive Investor in On steady million including in million our Care the continued by range financial and Care of of of around financial outlook outlook acquired line transition this million and At the million model. XXXX We trends to a profile the range consolidated growth impact $XXX result our Point Laboratory, Reset now of market is Element consumable key the share is on continued and November, time, acquisition is a expected as our the to increased multiyear estimate imaging, as AIM impact Point Day which continued million We year-over-year. $XX launch driver driven growth. of $XX global To to of gains, Growth revenue Point also are past of million to estimate financial Laboratory business we which $XXX acquisition,
the to are consistent to XX% be full-year XXXX PVD product segment, XXXX. lines from which anticipate outlook Point North rate Care and to estimated of an to our consolidated approximately than OVP of expected remaining We more relatively XX% XX%. America of revenues Lab growth consumable come of Our includes
margin relating international of is will by on rationalization XX% is North basis. includes be expected more margin, the transition, adjusted which XXXX than flat recognition Our instrument be AIM revenue to sales International expected Element X%. higher expected to consumable reset subscription continuation to and internationally growth Increased a be America. an rate program offset EBITDA reported in product approximately
additional increased mobility attributing at compared against XXXX, macro in expense the the in the operating to anticipate to margin among as sales are of of to in increased factors as Finally, force of relating we and COVID-XX light to sales-related travel scil compression quarter addition XXXX. vaccinations expense our
will assist and Lastly, which uncertainty, we $XX and change profile we GAAP no than to that's costs. this compensation for year, depreciation a of to investors we record million. still issuance statement approximately some on $XX Due million to on to applicable relatively noncash point of debt full other approximately notes X, forecast of the expense amortization income small related and analysts $XX to interest difficult a longer expect the January our of amortization due at stock-based our in to XXXX, guidance adopted instrument, accounting million amount convertible to
to Heska, net due we investment expect the $X related benefiting treatment expense approximately decisions interest of million. Additionally, accounting certain and
creating with specifically. pleased performance realizability to smaller initiatives. your is XXXX have With We projection, as open those discrete operations financial in In approximately future the which which believe as cash XXXX. tax the is are to in forward by for CapEx, many cash liquidity us sum, are to be million or $XX items as that, any assets any free we afforded and opportunities tax in strategic of look effective the rate valuation would changes full-year Operator? X% expected flow potential X% ongoing sufficient our for expense, XXXX less we for the compete deferred call to space will million. to we $X we Our questions. our for which and operating like Heska well we to flexibility flow defined excludes between on